XVIVO expands the US study with another leading transplant center

Barnes Jewish Hospital in St Louis, who pioneered lung transplantation, is the
tenth transplant center to participate in the NOVEL trial. The Organ Procurement
Organization (OPO) Mid-America Transplant Services has invested in an XPS in
order to strengthen the collaboration between transplant centers and OPO's. This
collaboration is the second of its kind in the USA.
Mid-American Transplant Services invested in an XPS™ and is collaborating with
Barnes-Jewish Hospital in order to increase the utilization of lungs and enable
transplants to more patients with severe lung disease. In 1988, Barnes-Jewish
Hospital became one of the first hospitals in the United States with a program
fully dedicated to lung transplantation surgery. The lung transplant program is
one of the world's largest with more than 1,000 adult transplant surgeries
performed.

The NOVEL trial was designed to safely increase the percentage of usable lungs
from the donor pool. It is being performed at 10 centers in the United States.
In the study, clinical outcomes after transplantation of lungs that have
undergone warm perfusion after having been initially discarded are compared with
a control group of lungs - non marginal - consisting of lungs that were
initially assessed as non-transplantable. The results of the study indicate that
lungs evaluated using STEEN Solution™ in an XPS™ do not differ in terms of
safety and function from lungs transplanted directly. These results are
consistent with those published from centers in Canada and Europe that have used
STEEN Solution™ clinically and an equivalent technique.

“We are pleased that another well-known center has joined the NOVEL trial and
that the connected OPO has invested in a XPS™. This collaboration is second of
its kind in the US and will increase the utilization of lungs and give
transplants to more patients with severe lung disease " says Dr. Magnus Nilsson
CEO of XVIVO Perfusion.

January 29, 2014
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

XVIVO Perfusion is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication
on Januray 29, 2014 at 2:00 p.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com